Education
About Us
Working with TipRanks
Follow Us
Clinical Laserthermia Systems AB Class B (DE:LS60)
FRANKFURT:LS60
LS60 Stock Chart & Stats
€0.59
<€0.01(0.74%)
At close: 4:00 PM EST
€0.59
<€0.01(0.74%)
Day’s Range― - ―
52-Week Range€0.18 - €1.16
Previous CloseN/A
Volume0.00
Average Volume (3M)75.00
Market Cap
€15.76M
Enterprise Value€120.47M
Total Cash (Recent Filing)€21.55M
Total Debt (Recent Filing)€0.00
Price to Earnings (P/E)―
Beta3.95
Next Earnings
May 15, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.04
Shares Outstanding31,163,593
10 Day Avg. Volume175
30 Day Avg. Volume75
Financial Highlights & Ratios
PEG Ratio0.07
Price to Book (P/B)2.55
Price to Sales (P/S)10.18
P/FCF Ratio-4.96
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)€5.07M
Bulls Say, Bears Say
Bulls Say
Low Leverage / Clean Balance SheetA near-zero debt position materially reduces financial risk and gives management flexibility to fund clinical rollouts or R&D without immediate interest burdens. Over the medium term this enhances options for non-dilutive financing, strategic partnerships, or measured capital investments to support commercialization.
Recurring Consumables And Service Revenue ModelA business model combining system sales with recurring disposables and service contracts creates a pathway to predictable, repeatable revenues once an installed base builds. Over months this can improve revenue visibility, raise marginal lifetime value per system, and support gross margin expansion as procedure volumes scale.
Clinical Collaboration And Integration FocusActive emphasis on clinical collaboration, system integration and procedure workflows helps overcome hospital adoption barriers. Durable clinical partnerships and workflow alignment increase likelihood of referral adoption, generate evidence for reimbursement, and shorten institutional procurement cycles over a multi-month to multi-year horizon.
Bears Say
Persistent Cash BurnSustained negative operating and free cash flow forces dependence on external financing or cash reserves, constraining the company's ability to scale commercial efforts or fund trials. Over several months this elevates dilution or refinancing risk and may limit hiring, sales footprint expansion, and long-term planning.
Small, Volatile Revenue BaseA small and inconsistent revenue stream undermines the ability to achieve installed-base scale necessary for recurring consumable and service revenue to offset fixed costs. Without stable top-line growth, margin improvements and predictable cash generation are unlikely within a 2–6 month horizon, hampering commercialization momentum.
Deep, Ongoing LossesVery large negative margins indicate the business has yet to validate unit economics at commercial scale. Persistent deep losses erode equity cushions and restrict reinvestment in sales, clinical studies, or product improvements, raising solvency and strategic flexibility concerns if improved margins are not realized over coming quarters.
LS60 FAQ
What was Clinical Laserthermia Systems AB Class B’s price range in the past 12 months?
Clinical Laserthermia Systems AB Class B lowest stock price was €0.18 and its highest was €1.16 in the past 12 months.
What is Clinical Laserthermia Systems AB Class B’s market cap?
Clinical Laserthermia Systems AB Class B’s market cap is €15.76M.
When is Clinical Laserthermia Systems AB Class B’s upcoming earnings report date?
Clinical Laserthermia Systems AB Class B’s upcoming earnings report date is May 15, 2026 which is in 71 days.
How were Clinical Laserthermia Systems AB Class B’s earnings last quarter?
Clinical Laserthermia Systems AB Class B released its earnings results on Feb 20, 2026. The company reported -€0.036 earnings per share for the quarter, missing the consensus estimate of N/A by -€0.036.
Is Clinical Laserthermia Systems AB Class B overvalued?
According to Wall Street analysts Clinical Laserthermia Systems AB Class B’s price is currently Overvalued.
Does Clinical Laserthermia Systems AB Class B pay dividends?
Clinical Laserthermia Systems AB Class B does not currently pay dividends.
What is Clinical Laserthermia Systems AB Class B’s EPS estimate?
Clinical Laserthermia Systems AB Class B’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Clinical Laserthermia Systems AB Class B have?
Clinical Laserthermia Systems AB Class B has 31,163,593 shares outstanding.
What happened to Clinical Laserthermia Systems AB Class B’s price movement after its last earnings report?
Clinical Laserthermia Systems AB Class B reported an EPS of -€0.036 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -23.125%.
Which hedge fund is a major shareholder of Clinical Laserthermia Systems AB Class B?
Currently, no hedge funds are holding shares in DE:LS60
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Clinical Laserthermia Systems AB Class B
Clinical Laserthermia Systems AB (publ) develops treatment tools for diseased tissue under the TRANBERG brand in Sweden. The company offers TRANBERG, a thermal therapy system designed to deliver laser energy to heat the target tissue. It also provides mobile laser unit, a controlling component with a wavelength of 1064 nanometers provides multiple options to control treatment. In addition, the company offers various gauge laser applicators, as well as provides temperature and treatment monitoring devices. Clinical Laserthermia Systems AB (publ) was incorporated in 2006 and is headquartered in Lund, Sweden.
Technical Analysis
SpectraCure AB
―
Luxbright AB
―
Scandinavian Real Heart AB
―
Nosa Plugs AB
―
Arcoma AB
―